Evaluation of GATA3 Gene Expression from Urothelial Carcinoma and theGenitourinary System: Its Correlation with Histopathological Parameters

Objective: Evaluation of the GATA3 utility in differentiating urothelial carcinoma from other malignant tumors of thegenitourinanry system such as prostatic adenocarcinoma, and renal cell carcinoma. And correlation between GATA3expression with other different parameters such as grade, stage, necrosis, and mitosis.Method: 70 cases of urothelial carcinoma, 10 cases of prostatic adenocarcinoma, and 10 cases of renal cell carcinoma ofpapillary and clear cell variants were selected at the period between (jan. 2017 and sep. 2020), with age range 34 to 88,with mean age 73 years, histopathologically evaluated, then stained with GATA3 antibody, and reevaluated with semiquantitative immunoreactive score, finally GATA3 correlated with tumor grade, stage, necrosis, and mitosis.Results: In this study GATA3 expressed in 84.3% of urothelial carcinoma cases, Expression used to be considerablycorrelated with tumor grade; ( p value = 0.001) and stage (p value = 0.003), but not with number of mitosis (p value = 0.2)or necrosis (p value = 0.7), None of the prostatic adenocarcinoma, or renal cell carcinoma express GATA3.Conclusion: GATA3 could be considered as a necessary precise sensitive and highly specific marker to confirm urothelialorigin. It is effective marker if used in the appropriate clinical concepts, GATA3 expression is an independent factorpredicting cancer recurrence, so it could be used as a prognostic marker not only diagnostic marker, No significantassociation found in this study between GATA3 expression and presence or absence of necrosis, or the number of mitosis.